Learn about the basics of fragment-based drug discovery (FBDD), one of the most valuable approaches to small molecule screening and now even more widely used today by pharma companies than high-throughput screening (HTS)
HTS’s main limitations — low success rates for more challenging targets, high level of false positives, and the size of the compound libraries — are propelling the use of FBDD. This change is also driven by the rise in the number of explorative targets, which demands not necessarily bigger libraries, but rather ones that contain more diverse molecules, especially from new chemical spaces. The benefit for the pharmaceutical industry as they adopt this approach is the improvement of hit rates and the delivery of higher-value targets.
What’s inside of the eBook
- Which strengths of fragment-based screening made it more popular than HTS
- Why biophysical methods are the perfect tools for fragment-based screening
- What the future holds for this screening approach